SAN FRANCISCO and COVINGTON, Ky., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization ...

UNIONDALE, N.Y. and ST. GALLEN, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced the Phase 3 trial of Angion’s ANG-3777 did not ...

Angion’s lead product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic currently being evaluating in a Phase 3 registration trial for delayed graft function in patients undergoing ...

UNIONDALE, N.Y. and ST. GALLEN, Switzerland, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced results from the exploratory Phase 2 GUARD trial of ...

UNIONDALE, N.Y.--(BUSINESS WIRE)--Angion Biomedica Corp. announced today that its Phase 2 “GUARD” clinical trial (GUard Against Renal Damage) using investigational drug BB3 in patients at risk for ...

SAN FRANCISCO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion), a clinical stage biopharmaceutical company developing first-in-class therapies to treat acute kidney injury and other ...

Angion Biomedica missed estimated earnings by 11.63%, reporting an EPS of $-0.48 versus an estimate of $-0.43. Revenue was up $1.28 million from the same period last year. Last quarter the company ...

* ANGION BIOMEDICA- INITIATED IN BRAZIL PHASE 2 CLINICAL TRIAL OF ANG-3777 IN PATIENTS WITH ACUTE LUNG INJURY ASSOCIATED WITH COVID-19 PNEUMONIA * ANGION SAYS CONDUCTING PHASE 3 REGISTRATION TRIAL OF ...

Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced results from the exploratory phase-II GUARD trial of Angion’s ANG-3777 in patients undergoing cardiac surgery involving ...

SAN FRANCISCO, July 08, 2020 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small ...